The Longevity Code Theme

People are living longer, and science is increasingly focused on helping them stay healthier for longer. This smallcase invests across the technologies and treatments driving that shift, from early scientific discovery to the healthcare solutions used in everyday medical care. 

• Advanced Genomics: Companies developing DNA sequencing, molecular diagnostics and gene-editing technologies that enable earlier diagnosis and more precise treatments. This is the earliest stage of healthcare innovation, offering the highest growth potential but also the highest risk.

• Medical Breakthroughs: Companies developing treatments for diseases commonly associated with ageing, providing direct exposure to areas where medical advances can improve quality of life.

• Elder Care & Chronic Disease Infrastructure: Companies making patient diagnostic, monitoring and treatment devices, and operators of senior living facilities for ageing populations

• Pharmaceuticals: Established pharmaceutical companies developing medicines across a broad range of chronic and age-related diseases, adding more mature and diversified exposure to the portfolio.

Together, these four segments provide exposure to the full healthcare innovation journey, from scientific discovery to approved treatments and the tools used to deliver them. Exposure to each segment is provided through carefully selected ETFs whose underlying holdings operate within these respective domains.